miR-1246在肝癌血清中的表达及对肝癌HepG2细胞生物学功能的影响

王攀; 王毅超; 虞丹丹; 陈文举; 钟倩怡; 童彬鑫

doi:10.16766/j.cnki.issn.1674-4152.002043

miR-1246在肝癌血清中的表达及对肝癌HepG2细胞生物学功能的影响

doi: 10.16766/j.cnki.issn.1674-4152.002043

1.
台州市中心医院(台州学院附属医院)医学检验科、台州学院分子诊断研究所，浙江台州 318000
2.
温州医科大学第一附属医院医学检验科，浙江温州 325000
3.
温州医科大学仁济学院医学技术与药学系，浙江温州 325000

基金项目:

浙江省科技计划项目 2018C37037

台州市科技计划项目 1901ky35

详细信息

通讯作者:
王毅超，E-mail：wangyc9359@tzzxyy.com

中图分类号: R735.7 R730.43
计量
- 文章访问数: 246
- HTML全文浏览量: 89
- PDF下载量: 2
- 被引次数: 0
出版历程
- 收稿日期: 2020-08-06
- 网络出版日期: 2022-02-16

Expression of microRNA-1246 in the serum of hepatocellular carcinoma and its effect on biological function of HepG2 cells

1.
Department of Clinical Laboratory Medicine, Taizhou Central Hospital (Taizhou University Hospital), Institute of Molecular Diagnosis, Taizhou, Zhejiang 318000, China

摘要

摘要: 目的探讨miR-1246在肝癌患者血清中的表达及其对HepG2细胞生物学功能的影响。方法应用荧光定量PCR检测miR-1246在正常对照者和肝癌患者血清中的表达；将miR-1246 mimics和NC mimics分别转染至HepG2细胞，采用Transwell小室法、划痕实验和细胞克隆形成实验检测miR-1246对HepG2细胞生物学功能的影响，荧光定量PCR检测NFE2L3、Vimentin、GAS1基因的表达改变。结果 miR-1246在正常对照者和肝癌患者血清中的表达量分别为1.079(0.740，1.534)、0.132(0.068，0.324)，差异有统计学意义(P < 0.001)；miR-1246 mimics转染HepG2细胞后，HepG2细胞穿过基质胶的细胞数为128.000±9.900, 较NC mimics组(251.500±24.749)明显减少(P=0.023)，划痕48 h后HepG2细胞相对迁移率为(24.833±3.351)%，较NC mimics组(31.859±7.194)%明显减慢(P=0.046)，Vimentin、GAS1、NFE2L3基因相对表达量分别为0.318±0.213、0.479±0.157、0.755±0.044，较NC mimics组(1.000±0.000)表达均明显下调(P=0.046、0.043、0.030)。结论肝癌患者血清中miR-1246表达下调；miR-1246可能通过下调Vimentin、GAS1、NFE2L3基因抑制HepG2细胞的侵袭、迁移能力。
- 肝癌 /
- miR-1246 /
- 侵袭 /
- 迁移
Abstract: Objective To investigate the expression of microRNA-1246 (miR-1246) in hepatocellular carcinoma (HCC) serum and its effect on the biological function of HepG2 cells. Methods Serum miR-1246 was determined by qRT-PCR in HCC patients and healthy controls. MiR-1246 mimics and NC mimics were transfected into HepG2 cells separately. The effect of miR-1246 on the biological function of HepG2 cells was examined by transwell chamber assay, scratch test and cell clone formation test. The expression of NFE2L3, Vimentin and GAS1 were detected by qRT-PCR. Results The expression levels of miR-1246 in the serum of healthy controls and HCC patients were 1.079 (0.740, 1.534) and 0.132 (0.068, 0.324), respectively, and the difference was statistically significant (P < 0.001). After transfection of miR-1246 mimics into HepG2 cells, the number of HepG2 cells passing through matrigel was (128.000±9.900), which was significantly lower than that of the NC mimic group (251.500±24.749, P=0.023). Forty-eight hours after scratch, the relative mobility of HepG2 cells was (24.833±3.351) %, which was significantly lower than that in the NC mimic group (31.859±7.194) % (P=0.046). The relative expression levels of Vimentin, GAS1 and NFE2L3 were (0.318±0.213), (0.479±0.157) and (0.755±0.044), respectively, which were significantly lower than those in the NC mimic group (P=0.046, P=0.043 and P=0.030, respectively). Conclusion The expression levels of miR-1246 were decreased in HCC serum. MiR-1246 could inhibit the invasion and migration of HepG2 cells by down-regulating the expression of Vimentin, GAS1 and NFE2L3.
- Hepatocellular carcinoma /
- MiR-1246 /
- Invasion /
- Migration

HTML全文

图 1 Transwell小室法实验结果(结晶紫染色，×40)

下载: 全尺寸图片幻灯片

图 2 划痕实验结果

注：A为NC mimics；B为miRNA-1246 mimics。

下载: 全尺寸图片幻灯片

图 3 过表达miR-1246对HepG2细胞增殖的影响

下载: 全尺寸图片幻灯片

参考文献(16)

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. doi: 10.3322/caac.21492
[2]	ZHANG P, SHAO G G, LIN X Y, et al. MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2[J]. Am J Cancer Res, 2017, 7(1): 53-63. http://ajcr.us/files/ajcr0046441.pdf
[3]	王攀, 赵玲萍, 朱杰, 等. 乳腺癌细胞中miR-1246、ZO-1、vimentin的表达及相关性研究[J]. 中华全科医学, 2016, 14(8): 1373-1375. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201608043.htm
[4]	GHEYTANCHI E, MADJD Z, JANANI L, et al. Exosomal microRNAs as potential circulating biomarkers in gastrointestinal tract cancers: a systematic review protocol[J]. Syst Rev, 2017, 6(1): 228. doi: 10.1186/s13643-017-0624-2
[5]	YANG F M, NING Z Q, MA L, et al. Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts[J]. Mol Cancer, 2017, 16(1): 148. doi: 10.1186/s12943-017-0718-4
[6]	MALLA B, ZAUGG K, VASSELLA E, et al. Exosomes and exosomal microRNAs in prostate cancer radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2017, 98(5): 982-995. doi: 10.1016/j.ijrobp.2017.03.031
[7]	李义. 血清miR-122作为肝癌手术预后的血清标志物的研究[J]. 中国医药导刊, 2016, 18(1): 93-94, 98. https://www.cnki.com.cn/Article/CJFDTOTAL-DKYY201601052.htm
[8]	曾勇, 程朋, 官泳松. 恩度联合动脉灌注化疗栓塞(TACE)治疗后原发性肝癌恶性程度的评估[J]. 海南医学院学报, 2016, 22(8): 799-802, 806. https://www.cnki.com.cn/Article/CJFDTOTAL-HNYY201608021.htm
[9]	CAO F, YIN L X. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway[J]. Exp Mol Pathol, 2019, 106: 34-43. doi: 10.1016/j.yexmp.2018.10.009
[10]	冯一鸣, 姚德生, 卢艳, 等. 宫颈鳞癌患者血清miR-1246的表达及其临床意义[J]. 肿瘤防治研究, 2019, 46(6): 532-536. doi: 10.3971/j.issn.1000-8578.2019.18.1727
[11]	HUANG W H, LI H F, LUO R C. The microRNA-1246 promotes metastasis in non-small cell lung cancer by targeting cytoplasmic polyadenylation element-binding protein 4[J]. Diagn Pathol, 2015, 10: 127. doi: 10.1186/s13000-015-0366-1
[12]	丁元杰, 马箐, 郭旭东, 等. 食管鳞癌患者血清差异表达miRNAs的筛选[J]. 山东医药, 2018, 58(15): 1-4. doi: 10.3969/j.issn.1002-266X.2018.15.001
[13]	解学军, 张冰. 外泌体MicroRNA-1246促进星形胶质瘤细胞增殖与侵袭的研究[J]. 中华细胞与干细胞杂志(电子版), 2018, 8(5): 292-296. doi: 10.3877/cma.j.issn.2095-1221.2018.05.006
[14]	ZHANG Q, CAO L Y, CHENG S J, et al. P53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB[J]. Oncol Rep, 2015, 33(3): 1335-1341. doi: 10.3892/or.2015.3715
[15]	彭兆意, 周喜洋. miR-1246在肝癌组织中的表达及其对人肝癌细胞增殖和凋亡的影响[J]. 肝胆胰外科杂志, 2016, 28(2): 98-101. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYW201602004.htm
[16]	SUN Z, MENG C T, WANG S H, et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 616. doi: 10.1186/1471-2407-14-616